{
    "Trade/Device Name(s)": [
        "GlucoLeader Enhance 2 Blood Glucose Monitoring System",
        "Enhance 2"
    ],
    "Submitter Information": "HMD BioMedical Inc.",
    "510(k) Number": "K212248",
    "Predicate Device Reference 510(k) Number(s)": [
        "K182428"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "August 29, 2022",
    "Summary Letter Received Date": "June 21, 2022",
    "Submission Date": "June 10, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood (fingertip)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GlucoLeader Enhance 2 Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometry glucose biosensor"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip",
        "Control Solution",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for GlucoLeader Enhance 2 Blood Glucose Monitoring System for self-monitoring blood glucose in capillary whole blood.",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from the fingertip for self-testing by people with diabetes at home, not for diagnosis or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}